INTRODUCTION AND AIMS:
Hyperkalaemia is associated with adverse clinical outcomes in patients with chronic kidney disease (CKD). This real-world analysis investigated the incidence and recurrence of hyperkalaemia in incident CKD stage 3þ patients in the UK, and the excess length-of-stay and mortality of these patients following admission to hospital. METHODS: This retrospective observational cohort study utilised patient records from the Clinical Practice Research Datalink and Hospital Episodes Statistics (HES), from Jan 2006 to Dec 2015. Patients with eGFR &#8804;60mL/min/1.73m 2 or a diagnosis/admission code for CKD stage 3þ during the study period were included. Patients with a history of CKD or heart failure prior to the study period were excluded, or if dialysis was their first renal event. A hyperkalaemia episode was defined as a serum potassium measurement 5.0 mmol/L, without a similar measurement in the preceding seven days. Median time between successive hyperkalaemia episodes was quantified among patients experiencing the given number of episodes (ignoring censoring). Hospital admissions in hyperkalaemic patients were matched to those in non-hyperkalaemic patients on age, gender and primary diagnosis. Differences in mean length-ofstay and odds ratios associated with in-hospital/30-day-post-discharge mortality between the two groups were estimated using Generalised Estimating Equations. RESULTS: A total of 306,569 hyperkalaemia episodes were observed in 191,964 patients, at a rate of 321.9 episodes per 1,000 patient-years (95% confidence interval: 320.7-323.0). Hyperkalaemia was experienced by 48.4% of the cohort, with 28.8% experiencing multiple episodes. The probability of multiple episodes increased with renal function decline, and was greater for females than males, patients with diabetes than those without, and patients in receipt of RAASi than those not in receipt (all p<0.0001). The median time from initial CKD event to first hyperkalaemia episode (among patients who experienced at least one episode) was 1.7 years, falling to 0.9 years from first to second episode, 0.6 years from second to third episode, and 0.5 years from third to fourth episode. HES records could be linked to 99,995 patients; mean lengthof-stay among 55,439 hospital admissions of hyperkalaemic patients was 10.6 days, 3.5% longer than in the matched non-hyperkalaemic cohort (p<0.0001), and increasing to 12.9% (p¼0.0003) for severe hyperkalaemia (6.0 mmol/L). The odds of in-hospital/post-discharge mortality was 20% greater for patients with hyperkalaemia (p<0.0001). CONCLUSIONS: Recurrent hyperkalaemia was common among incident CKD stage 3þ patients in the UK. Hyperkalaemia was more frequent after each successive episode, with increasingly shorter intervals between episodes. Hospitalised patients with hyperkalaemia tended to remain in hospital longer than those without hyperkalaemia, therefore placing a greater burden on the healthcare system, and were more likely to die during or shortly after the admission. Hypertension and chronic kidney disease are related, and uncontrolled hypertension increases the risk of progression in chronic kidney disease. 50 % of patients suffering from a chronic disease are non-adherent, which is associated with inadequate disease control. The aim of this study is to investigate and explore adherence and beliefs about medicine among chronic kidney disease patients in treatment with antihypertensives or lipid-lowering drugs. METHODS: A mixed methods approach was used combining questionnaires and semi-structured interviews. Patients aged over 18 with a chronic kidney disease were included. The questionnaire included Beliefs about Medicine Questionnaire (BMQ) to measure beliefs and Danish Medication Adherence Report Scale (D-MARS) to measure adherence. Qualitative semi-structured interviews were conducted to explore attitude, perception, and knowledge about medicine. Transcripts were systematically themed and condensed. RESULTS: 86 participants completed the questionnaire and were included in the statistical analysis. The average age of the participants was 60.3 years (SD 6 11.3). Of participants in treatment with antihypertensives, 85.4 % had high adherence, whereas 87.2 % of participants in treatment with lipid-lowering drugs had high adherence. Medium/ low adherers had significant lower age than high adherers and were more concerned about their treatment. 13 of the 86 participants who answered the questionnaire were interviewed and included in the qualitative analysis. The appearing themes were mapped against a theoretical framework of this study which was derived mainly from The five dimensions of adherence proposed by the World Health Organization. The main themes were patient-related factors (disease and medicine knowledge, health and disease perception, attitude towards medicine, self-management, disease and medicine concerns), therapy-and condition-related factors (side effects and asymptomatic disease), health care team and system-related factors (patient-physician relationship), and social and economic factors (family support). CONCLUSIONS: Patient-related factors were the most prominent themes among the interviewed participants. Concerns about medicine and younger age were associated with non-adherence. Concerns were identified as fears of side effects and drug interactions. 
Little is known about the burden of hospitalisations in non end-stage chronic kidney disease (CKD). We assessed hospitalisation rates, duration, and causes in patients with moderate and advanced CKD under nephrology care. METHODS: The CKD-REIN study is a prospective cohort which included 3033 outpatients (65% men) with CKD and estimated glomerular filtration rate (eGFR) of 15-60 mL/min per 1.73 m 2 at 40 nationally representative public and private nephrology clinics in France. Hospitalisations with at least 1 night, day-hospitalisations, and emergency visits were recorded over a 2-yr follow-up. RESULTS: At baseline, patients' median age was 69 (IQR, 60-76), their mean eGFR was 33 mL/min per 1.73 m 2 , and 36% had albuminuria > 30 mg/mmol (or proteinuria >50). Distribution of cohort participants according to KDIGO 2012 eGFR*albuminuria risk categories and prevalence of comorbidities are shown in the Table below. Over 2-yr follow-up, there were 282 deaths and 380 ESRD. A total of 4978 hospitalisations occurred before ESRD of which 2648 1 night, i.e., 24.3 [95% CI, per 100 person-years. Median number of hospitalisations 1 night per patient was 2[IQR, 1-3]; their median duration was 5 [IQR, [3] [4] [5] [6] [7] [8] [9] [10] [11] days. The two most common causes of hospitalisation were cardiovascular disease (24%), mainly cardiac failure, and acute kidney injury (13%). CKD risk category, comorbidities, and care in public vs private nephrology clinics were significantly associated with higher hospitalisation risks (Table) . CONCLUSIONS: The burden of hospitalisation is high in patients with CKD under nephrology care and strongly related to CKD severity and associated comorbidities. 
